Create bliss. Abolish suffering. 

Smart drugs for mental health.

Learn more 

About Us


We have developed a drug design algorithm, integrated within our therapeutic discovery platform, CANDO (Computational Analysis of Novel Drug Opportunities), which leverages multiscale data to rapidly generate unique, effective, and safe drugs de novo. The novelty of this approach lies in the use of full organismal proteomes to tailor molecules for specific therapeutic uses, while considering toxicity and other pharmacological properties. This approach is in direct contrast to traditional drug discovery pipelines in which a single protein target is used in a large-scale screen of compounds/drugs for a single disease/indication.

With CANDO, we will generate drug candidates that enhance quality of life (such as improving cognition and reducing pain) with negligible side effects (such as reducing substance abuse potential). 


William Mangione, Ph.D.

CEO and co-founder

Zackary Falls, Ph.D.

CSO and co-founder

Brennan Overhoff

COO and co-founder

Matthew Muhoberac


Gaurav Chopra, Ph.D.


Ram Samudrala, Ph.D.


Scientific Advisors

Jun-Xu Li, Ph.D.

Scientific Advisor

Peter Thanos, Ph.D.

Scientific Advisor

Media and Publications

Shotgun Drug Repurposing Aids Fight Against COVID-19

University at Buffalo School of Medicine 

2020 NCATS ASPIRE Reduction-to-Practice Challenge Winners

National Center for Advancing Translational Sciences Open Source Software for Predictive Bioanalytics of Large Scale Drug–Protein–Disease Data

Journal of Chemical Information and Modeling 


Lead design

Lead synthesis


Phase I

Phase II

Phase III

Substance use disorder


Non-addictive analgesics


Cognition enhancement